



OPEN ACCESS

EDITED BY

Caterina Di Bella,
University of Camerino, Italy

REVIEWED BY

Federica Alessandra Brioschi,
University of Milan, Italy
Lauri-Jo Gamble,
Cornell University, United States

*CORRESPONDENCE

Daniel Mota-Rojas
✉ dmota100@yahoo.com.mx
Ismael Hernández-Ávalos
✉ mvzih@hotmail.com

SPECIALTY SECTION

This article was submitted to
Veterinary Surgery and Anesthesiology,
a section of the journal
Frontiers in Veterinary Science

RECEIVED 22 September 2022

ACCEPTED 13 December 2022

PUBLISHED 04 January 2023

CITATION

Miranda-Cortés A, Mota-Rojas D,
Crosignani-Outeda N,
Casas-Alvarado A, Martínez-Burnes J,
Olmos-Hernández A, Mora-Medina P,
Verduzco-Mendoza A and
Hernández-Ávalos I (2023) The role of
cannabinoids in pain modulation in
companion animals.
Front. Vet. Sci. 9:1050884.
doi: 10.3389/fvets.2022.1050884

COPYRIGHT

© 2023 Miranda-Cortés, Mota-Rojas,
Crosignani-Outeda, Casas-Alvarado,
Martínez-Burnes, Olmos-Hernández,
Mora-Medina, Verduzco-Mendoza and
Hernández-Ávalos. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which
does not comply with these terms.

The role of cannabinoids in pain modulation in companion animals

Agatha Miranda-Cortés¹, Daniel Mota-Rojas^{2*},
Nadia Crosignani-Outeda³, Alejandro Casas-Alvarado²,
Julio Martínez-Burnes⁴, Adriana Olmos-Hernández⁵,
Patricia Mora-Medina⁶, Antonio Verduzco-Mendoza⁵ and
Ismael Hernández-Ávalos^{1*}

¹Department of Biological Science, Clinical Pharmacology and Veterinary Anesthesia, Universidad Nacional Autónoma de México (UNAM), FESC, Mexico City, Mexico, ²Neurophysiology of Pain, Behavior and Assessment of Welfare in Domestic Animals, DPAA, Universidad Autónoma Metropolitana, (UAM), Mexico City, Mexico, ³Department of Clinics and Veterinary Hospital, School of Veterinary, University of Republic, Montevideo, Uruguay, ⁴Animal Health Group, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Tamaulipas, Ciudad Victoria, Tamaulipas, Mexico, ⁵Department Bioterio and Experimental Surgery, Instituto Nacional de Rehabilitación-Luis Guillermo Ibarra Ibarra (INR-LGII), Calzada México Xochimilco, Mexico City, Mexico, ⁶Livestock Science Department, Universidad Nacional Autónoma de México (UNAM), FESC, Mexico City, Mexico

The use of cannabinoids in both veterinary and human medicine is controversial for legal and ethical reasons. Nonetheless, the availability and therapeutic use of naturally occurring or synthetic phytocannabinoids, such as Δ^9 -tetrahydrocannabinol and cannabidiol, have been the focus of attention in studies regarding their medical uses. This review aims to examine the role of cannabinoids in pain modulation by analyzing scientific findings regarding the signaling pathways of the endocannabinoid system and discussing the analgesic effects of synthetic cannabinoids compared to cannabinoid extracts and the extent and involvement of their receptors. In animals, studies have shown the analgesic properties of these substances and the role of the cannabinoid binding –1 (CB1) and cannabinoid binding –2 (CB2) receptors in the endocannabinoid system to modulate acute, chronic and neuropathic pain. This system consists of three main components: endogenous ligands (anandamide and 2-arachidonoylglycerol), G protein-coupled receptors and enzymes that degrade and recycle the ligands. Evidence suggests that their interaction with CB1 receptors inhibits signaling in pain pathways and causes psychoactive effects. On the other hand, CB2 receptors are associated with anti-inflammatory and analgesic reactions and effects on the immune system. Cannabis extracts and their synthetic derivatives are an effective therapeutic tool that contributes to compassionate pain care and participates in its multimodal management. However, the endocannabinoid system interacts with different endogenous ligands and neurotransmitters, thus offering other therapeutic possibilities in dogs and cats, such is the case of those patients who suffer from seizures or epilepsy, contact and atopic dermatitis, degenerative myelopathies, asthma, diabetes and glaucoma, among other inflammatory diseases. Moreover, these compounds have been shown to possess antineoplastic, appetite-stimulating, and antiemetic properties.

Ultimately, the study of the endocannabinoid system, its ligands, receptors, mechanism of action, and signaling, has contributed to the development of research that shows that hemp-derived and their synthetic derivatives are an effective therapeutic alternative in the multimodal management of pain in dogs and cats due to their ability to prevent peripheral and central sensitization.

KEYWORDS

analgesia, animal welfare, cannabinoid receptors, endocannabinoid system, marijuana

Introduction

The use of cannabinoids in human and veterinary medicine has been controversial for ethical and legal reasons. Despite this, hemp-derived compounds are gaining medical approval for their benefits. However, drug use is complicated by the application of laws and professional regulations of each country (1), so further research is needed to document and support their clinical use (2). Cannabinoids are a group of compounds obtained from hemp (*Cannabis sativa* L.) that have been used for different therapeutic purposes in dogs, cats, and ferrets (2, 3): antispasmodics, antiemetics, anticonvulsants, and appetite stimulants, or for their neuroprotective, analgesic and anti-inflammatory properties. Other documented uses in rodent models are as a treatment for cancer, asthma, diabetes, and retinitis pigmentosa (3). They also could be effective in managing pain related to osteoarthritis (2–4), which has prompted owners of companion animals to use cannabinoids as a natural alternative with potential benefits (5).

Several controlled clinical trials were initiated over 20 years ago to treat various pathologies using cannabinoids. These substances have been used to treat health problems such as cephalgia, fever, bacterial infections, diarrhea, rheumatic pain, or malaria (4, 6). These resulted in the approval of cannabis-based products such as dronabinol, nabilone, and an extract of delta-9-tetrahydrocannabinol (Δ^9 -THC) and cannabidiol (CBD) (7). The total synthesis of (-) and (+) optical isomers was first published in 1965 (8). Later in 1988, after the discovery of the first endogenous cannabinoids, several studies were carried out that described the participation of the endocannabinoid system to control nausea and pain related to cancer or to reduce these signs produced by antineoplastic treatments (9, 10).

This review aims to analyze and describe the pharmacokinetic and pharmacodynamic characteristics of cannabinoids and the spatial distribution of their receptors, focusing on their role in the modulation of pain in companion animals. It will discuss and compare the analgesic effect of synthetic cannabinoids and extracts and analyze scientific findings regarding the endocannabinoid system's signaling pathways and its receptors' range and participation.

Chemical structure

Cannabinoids have a carboxylic chemical structure with 21 carbons consisting of three rings: cyclohexane, tetrahydropyran, and benzene (10, 11). To study cannabinoids, researchers have classified them as chemical substances that interact with specific receptors, divided into three groups: herbal cannabinoids (phytocannabinoids), endogenous cannabinoids (endocannabinoids), which can be found in human or animal organisms, and synthetic cannabinoids (3, 10, 12). The word tetrahydrocannabinol (THC) is generally used to designate the (-)-trans- Δ^9 -tetrahydrocannabinol isomer (dronabinol, previously 1-, 3,4-trans-tetrahydrocannabinol), which can be linked to most pharmacological effects of cannabis, including its psychoactive properties. On the other hand, CBD is the most studied important non-psychoactive found in cannabis (13, 14).


To date, 489 chemical compounds have been identified, 70 belonging to the phytocannabinoids group and its subcategories. THC and CBD have been particularly relevant in pharmacological therapy. Δ^9 -THC has a tri-cyclic 21-carbon structure without nitrogen and two chiral centers in trans configuration; it is volatile viscous oil with high lipid solubility and low aqueous solubility, and a pKa of 10.6 (15). Δ^9 -THC has been shown to interact with type 1 and 2 receptors, with a particular affinity with type 2 receptors. In contrast, CBD has a lesser affinity to both receptors (16–18). The chemical name of CBD is 5'-methyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro-1,1'-biphenyl]-2,6-dioles retaining the trans-(1R,6R) (19).

On a physiological level, endocannabinoids act as endogenous ligands for the anandamide and 2-arachidonoylglycerol (2-AG) receptors, which regulate and modulate nociception, lipid metabolism, and gastrointestinal, cardiovascular, and motor functions (19, 20). Synthetic analogs have a similar structure to phytocannabinoids and are synthesized to mimic their effects (21). As their use increases, more studies have tried to manufacture different products for medical purposes, such as HU-210, considered a CB1 and CB2 agonist (3, 14, 22).

Pharmacokinetic characteristics

In dogs and cats, cannabinoid pharmacokinetic studies suggest administering different doses of THC, CBD, or products that contain both phytocannabinoids by oral, transmucosal, transdermal, intravenous and sublingual routes, where the majority of these products are made from hemp (12, 23, 24). The main phytocannabinoids reported are terpenes, flavonoids, CBD, cannabidiolic acid (CBDA) and THC, which should be considered as the main factor influencing the evaluation of a pharmacokinetic response since most products do not have a commercial standardization available for regulation and investigation. Despite this limitation, there is sufficient evidence of its pharmacokinetic characteristics (25). **Absorption.** Cannabinoids are easily absorbed due to their hydrophobic and liposoluble properties (11), although they are difficult to excrete without significant biotransformation. **Distribution.** Lipophilic drugs make a second plasma peak common due to slow gastric emptying, redistribution, and even different absorption windows in the gastrointestinal tract. When these substances are administered orally or intravenously, they bind to lipoproteins, albumin, and erythrocytes once in the bloodstream. Cannabinoids can bind to CB1 and CB2 receptors in the Central Nervous System (CNS) and the

Peripheral Nervous System (PNS), and the effects can be seen 0.5 to 2 h after being administered (26, 27). In addition, they may accumulate in adipose tissue, liver, lungs, spleen, brain, and muscles, with subsequent continued release after the rapid initial reduction of their plasma levels. CBD and THC may reach a steady state with continuous treatments or high doses in a short period (3, 7). **Metabolism.** When used orally, phytocannabinoids show first-pass metabolism. Natural derivatives, such as Δ^9 -THC are metabolized through hydroxylation, decarboxylation, and liver conjugation, by the action of CYP2C isozymes of cytochrome 450. They can also be metabolized in extrahepatic tissues such as the intestine and the lungs. 11-hydroxy- Δ^9 -THC (11-OH-THC), still an active metabolite, is created due to this biotransformation (28–30). There is evidence that THC and CBD can cause interference with the activity of several hepatic cytochrome p450 enzymes' families. Thus, the association of phytocannabinoids with concurrently administered therapies may increase the serum levels of other drugs (28). **Excretion.** Eliminating these compounds by the fecal route includes biliary excretion, so enterohepatic recirculation is possible. Cannabinoids suffer from β - and α -elimination reactions before urinary excretion. Clinical trials in dogs and cats revealed an elimination half-life of 1.0–1.5 h when administered orally, although, in dogs



with osteoarthritis (OA) treated with CBD at doses of 2 mg/kg, times of 3.8–6.8 h are reported, which showed no difference when doses >8 mg/kg were used, where the elimination half-life was 3.8–4.8 h (30). Figure 1 summarizes the pharmacokinetics of the phytocannabinoids used in veterinary medicine (10, 18, 29).

The pharmacokinetic parameters can be influenced by the products used as raw materials to prepare the extracts (8, 31). For example, in a study by Deabold et al. (23), the pharmacokinetics of oral (soft chews for dogs and oil for cats) administration of CBD and CBDA obtained from hemp at a single dose of 2 mg/kg (based on CBD) every 12 h for 12 weeks was evaluated in healthy dogs and cats. A mean maximum concentration (C_{max}) of 301 ng/mL in dogs and 43 ng/mL in cats, an area under the curve (AUC) of 1,297 ng/h/mL and 164 ng/h/mL, respectively, was observed. The time to reach the maximum concentration of CBD (T_{max}) was 1.4 h in dogs and 2 h in cats, indicating a significant difference in the pharmacokinetic parameters between these species (23). These pharmacokinetic differences also became apparent when a transdermal CBD-CBDA-rich extract was used in dogs, where serum concentrations of CBD, CBDA, THC, and its acid derivative tetrahydrocannabinolic acid (THCA) were examined. A 4 mg/kg dose of total cannabinoids twice daily resulted in appx 10 ng/ml of CBD, 21–32 ng/ml of CBDA, trace amounts of THCA, and unquantifiable amounts of THC in serum at the end of 1–2 weeks of treatment, concluding that CBDA and THCA were absorbed better systemically (32). In escalated doses, cannabis oils, including a CBD-predominant oil (2.8–30.5 mg/kg CBD + 0.1–1.1 mg/kg THC), a THC-predominant oil (3.8–41.5 mg/kg THC) and a CBD/THC-predominant oil (1.2–13 mg/kg CBD + 0.8–8.4 mg/kg THC) were studied in cats (33). An interaction of CBD and THC was observed, with higher plasma cannabinoid and metabolite levels following the administration of CBD/THC combination products. Cats appear to have lower serum concentration and faster CBD elimination than dogs (33). Other clinical studies on the pharmacokinetic characteristics of CBD are summarized in Table 1 (23, 30, 31, 34–37).

Pharmacodynamics and receptors in the endocannabinoid system

The endocannabinoid system is a signaling pathway found in most vertebrates (30) and regulates various body functions (38). This system consists of three main components: endogenous ligands (anandamide and 2-AG), G-protein coupled receptors and enzymes that degrade and recycle the ligands (39). These enzymes are widely distributed in the organism in levels called the “endocannabinoid tone,” which varies according to the tissue involved (40).

In 1992, Anandamide (N-arachidonoyl-ethanolamine), 2-AG, and 2-arachidonoyl glyceryl ether (2-AGE), O-arachidonoyl

ethanolamine (virodhamine), and N-arachidonoyl dopamine (NADA) were identified as endogenous agonists of cannabinoid receptors (35). These molecules are locally produced in the cell membrane by hydrolysis of polyunsaturated fatty acids (41). When metabotropic glutamate receptors are activated or in response to an increase in intracellular Ca²⁺, they are released from postsynaptic neurons due to depolarization (3).

Anandamide and phytocannabinoids are competitively bound to cannabinoid receptors in the presynaptic and postsynaptic membranes of the neurons found in astrocytes, oligodendrocytes, and microglia cells. They can modulate the postsynaptic neuron's excitability in the cell membrane (42, 43) and stimulate Gi/o proteins and mitogen-activated protein kinases (MAPK), causing the inhibition of adenylyl cyclase and voltage-dependent Ca²⁺ channels (Figure 2) (10, 18, 29, 40). This mechanism reduces the release of noradrenaline, acetylcholine, glutamate, GABA, glycine, aspartate, serotonin (5HT), dopamine, cholecystokinin (9, 44), and secretion of dynorphins and β-endorphins (16, 45).

Evidence shows that endogenous cannabinoids are linked to a ubiquitous regulating system (30) that involves a group of CB1 (cannabinoid binding 1) and CB2 (cannabinoid binding 2) receptors bound to protein G (GPCR) type Gi/o (39, 46). Once activated, they will retrogradely inhibit neurotransmitters such as gamma-aminobutyric acid (GABA) and glutamate. Other G protein-associated receptors are GPR3, GPR6, GPR12, GPR18, GPR55, and GPR119.

Studies show that the endocannabinoid system is expressed and linked to the nociceptive pathway, where receptors can be found in ascending and descending pain fibers (47). These receptors have also been found in the CNS in presynaptic and postsynaptic GABAergic neurons on the dendritic and somatic surface area of the cerebellum, hippocampus, cerebral cortex, and spinal cord, structures involved in pain modulation (21, 48). G protein-coupled receptor 55 (GPR55 or CB3) is also found in the CNS, but to a lesser extent than CB1 (49).

On the other hand, CB2 is mainly expressed in peripheral tissues and immune and glial cells (3). As a result, they could be involved in sensitizing nociceptive fibers when an immune response has been triggered (50). Studies in rats and dogs have shown the presence of receptors termed peroxisome proliferator-activated receptor alpha, gamma, and beta (PPAR_α, PPAR_γ, PPAR_β), transient receptor potential ankyrin 1 (TRPA1), vanilloid receptor (TRPV1, TRPV2, TRPV3, TRPV4), transient receptor potential (TPR) channels, and the serotonin 5-HT_{1A} receptor (5-HT_{1A}R) (51, 52).

Research in rodents, dogs, cats, and monkeys has shown cannabinoid receptor subtypes, CB1, CB2, and GPR55 (cloned in 1990, 1993, and 1995 respectively), linked to G protein-coupled receptors (18, 46). However, differences have been found among them, such as their number of amino acids, tissue distribution, and sensitivity to specific agonists and antagonists that show selectivity for one or the other receptor (14).

TABLE 1 Pharmacokinetic studies with different pharmaceutical forms of CBD.


Pharmaceutical form	Absorption kinetics		Distribution kinetics	Species	Reference
	Dose	Evaluated parameters			
Oral CBD Hemp based-product (oil)	2 mg/kg total CBD concentration orally twice daily for 12 weeks	Pharmacokinetics parameters Serum chemistry and complete blood counts showed no clinically significant alterations; however one cat showed a persistent rise in alanine aminotransferase (ALT) above the reference range for the duration of the trial. Cats absorb or eliminate CBD differently than dogs, showing lower serum concentrations and adverse effects of excessive licking and head-shaking during oil administration	Cmax) of 301 ng/mL and 43 ng/mL, area under the curve (AUC) of 1,297 ng-h/mL and 164 ng-h/mL, and time to maximal concentration (Tmax) of 1.4 and 2 h, for dogs and cats, respectively	Dogs and cats	Deabold et al. (23)
CBD oil	2 mg/kg oral 8 mg/kg oral	Single-dose pharmacokinetics was performed using two different doses of CBD enriched in osteoarthritic dogs. Each treatment lasted for 4 weeks with a 2-week washout period. The Veterinary assessment showed decreased pain during CBD treatment ($p < 0.02$). Serum chemistry showed an increase in alkaline phosphatase during CBD treatment	Cmax of CBD oil was 102.3 ng/mL (60.7–132.0 ng/mL; 180 nM) and 590.8 ng/mL (389.5–904.5 ng/mL; 1.2 μ M) and was reached after 1.5 and 2 h, respectively, for 2 and 8 mg/kg doses Elimination half-life of 4.2 h at both doses and no observable side effects. Clinically, canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and an increase in activity ($p < 0.01$) in patients treated with CBD oil	Dogs	Gamble et al. (30)
Three oral forms of CBD-rich hemp extract Form 1 (Oil A) being a mix of 25% medium-chain triglycerides and 75% long-chain triglyceride. Each milliliter contained 28 mg of CBD, 29 mg of CBDA, 1 mg of THC, 0.8 mg THCA, 0.7 mg of cannabigerolic acid (CBGA), and 1.3 mg of cannabichromene (CBC). Form 2 (Oil B), 25% of the base oil was from sunflower lecithin; 75% of organic sesame oil as Form 1. Form 3, contained ~5 mg of CBDA and 5 mg of CBD in each soft chew.	2 mg/kg of CBD/CBDA (~1 mg/kg CBD and ~1 mg/kg CBDA). Dogs were dosed every 12 h for 2 weeks	CBD, CBDA, THC, and THCA. In addition, metabolized psychoactive component of THC, 11-hydroxy- Δ^9 -tetrahydrocannabinol (11-OH-THC) and CBD metabolites 7-hydroxycannabidiol (7-OH-CBD) and 7-nor-7-carboxycannabidiol (7-COOH-CBD)	No differences were noted for Tmax, T $\frac{1}{2}$, AUC and MRT. Significant difference in CBD. Form 3 have a higher Cmax than Form 2, but not Form 1 ($p = 0.03$). Values were 226 vs. 124 ng/ml respectively THC concentrations could not be compared over the 24-h time period due to insufficient data THCA had extensive absorption and higher serum concentrations that were statistically significant between forms. Tmax of 3.3 ng/ml (form 3) vs. 2.2 ng/ml (form 2) and 1.7 ng/ml (form 1). The 7-COOH-CBD concentrations could be compared between Form 2 and Form 3, showing significant differences in Cmax being slightly higher for Form 3 over Form 2 ($p = 0.02$) The metabolites of THC, 11-OH-THC, and COOH-THC-Glu were all below the lower limit of quantitation (1 ng/mL for THC or 2.5 ng/mL for 11-OH-THC and COOH-THC-Glu) A partial lecithin base provides superior absorption and/or retention of CBDA and THCA. No significant changes were observed in ALP, ALT, AST, albumin, total bilirubin, cholesterol and glucose	Dogs	Wakshlag et al. (31)
CBD IV CBD oral	45 mg IV 90 mg IV 180 mg, oral	Doses of 45 to 90 mg generated a proportional increase in AUC, indicating that the pharmacokinetic profile of CBD was not dependent on the administered dose. Three dogs did not record CBD concentrations in plasma after oral administration, and the oral bioavailability was 13–19% in dogs where absorption was observed	CBD IV had a terminal half-life of 9 h, with a triphasic decrease in plasma levels. Plasma clearance was 17 liters/h (at 45 mg doses) and 16 liters/h (after 90 mg). The liver extraction rate was 0.74. Vd of 100 liters	Dogs	Samara et al. (34)

(Continued)

TABLE 1 (Continued)

Pharmaceutical form	Absorption kinetics		Distribution kinetics	Species	Reference
	Dose	Evaluated parameters			
Oral CBD- infused oil Oral microencapsulated CBD-oil beads CBD-infused transdermal cream	75 or 150 mg/ 12 h/ 6 week	75 mg dose: Relative bioavailability of 100, 70.1 and 8.6 % for each formulation, respectively Cmax 625.3; 346.3 and 74.3 ng/mL, respectively 150 mg dose: Bioavailability of 100, 54.7 and 9.9 % for each formulation used respectively Cmax 845.5; 578.1 and 277.6 ng/mL, respectively	75 mg dose MRT of 217, 353 and 490 min average for each formulation used respectively T1/2 of 199.7 y 95.4 min for infused oil and microencapsulated oil. In transdermal cream this was not determined 150 mg dose MRT of 298, 332 and 464 min average for each formulation used, respectively T1/2 of 127.5 y 115.9 min for infused oil and microencapsulated oil. Likewise, in transdermal cream was not determined	Dogs	Bartner et al. (35)
Sativex®	Sublingual administration of single doses of 3 consecutive sprays Doses of 3 sprays daily for 14 days	Cmax Δ^9 -THC = 18.5 ng/ml) and Cmax CBD = 10.5 ng/ml, both at 2 h post-administration in the single dose condition. Cmax Δ^9 -THC = 24.5 ng at 1 h post-treatment AUC in a single dose was 94.9 ng/ml/h for Δ^9 -THC and 60.4 ng/ml/h for CBD, observing a similar profile after 14 days of treatment when multiple doses were used. Possible progressive accumulation of CBD and Δ^9 -THC was detected after repeated exposure	Metabolite 11-Hydroxy- Δ^9 -THC produced in the liver from Δ^9 -THC, was almost undetectable, with values for AUC = 6.8 ng/ml/h, Cmax = 1.2 ng/ml and Tmax = 2 h when single dose was used. While AUC = 18.2 ng/ml/h, Cmax = 2.2 ng/ml and Tmax = 2 h in dogs that received multiple doses	Dogs	Fernández-Trapero et al. (36)
Cannabis herbal extract (1:20 THC-CBD)	Single-dose oral at low, medium, or high doses [2, 5, or 10 mg CBD and 0.1, 0.25, or 0.5 mg THC/Kg, respectively	Dogs were monitored for adverse events for up to 48 h post-dose. Evaluations of neurological signs, clinical laboratory abnormalities, and other adverse events were performed in two separate study phases: a multiple-dose phase with 12 dogs receiving five medium doses (5 mg CBD/kg bw) at 12 h intervals and a single low-dose (2 mg CBD/kg bw)	CBD, THC, CBC, and metabolites 6-OH-CBD, 7-OH-CBD, 11-OH-THC, and THC-COOH were quantified in the plasma until 48 h post-administration. CBD and THC: Tmax of 1.9–2.3 h and T1/2 of 2.3–2.6 h. A prolonged elimination phase (CBD T1/2 of 13.3–24.4 h) was observed CBD and THC concentrations increased in a dose-dependent (non-linear) manner. Neurological signs (hyperesthesia or proprioceptive deficits) were noted in 5/6 dogs in the high-dose group but only occasionally or rarely in the medium- and low-dose groups. No clinically meaningful changes in blood count or chemistry values occurred after multiple CHE doses	Dogs	Chicoine et al. (37)

AUC, area under the curve; CBD, cannabidiol; Cmax, maximal concentration; IV, intravenous; MRT, mean residence time; T1/2, half-life; Tmax, mean observed time of maximum concentration; Vd, volume distribution.



CB₁, CB₂, and GPR55 receptors identified in dogs have led to *Cannabis sativa* extracts for effective pain control, such as Δ⁹-THC and CBD (16). It has been suggested that the lipophilic properties of cannabinoids enable them to easily cross the blood-brain barrier (53, 54) and cause analgesia, thus rendering them effective in treating pain. Nonetheless, there is still some debate about whether the pain control mechanism of cannabinoids occurs as a result of the CB₁ and CB₂ receptors agonism or due to the effects caused by the interaction with neuromodulators and the inhibition of neurotransmitters such as glutamate, dopamine, prostaglandins, acetylcholine, GABA, histamine, noradrenaline, and endogenous opioid peptides involved in pain modulation for dogs and cats (3, 55, 56).

It has been reported that cannabinoids can decrease tolerance and maintain response to other drugs after repetitive administration, such as opioids used to treat chronic and acute pain in rodent models (57, 58). As a result, the use of cannabinoids has been suggested as multimodal pain management without adverse effects in the gastrointestinal tract or glomerular filtration (57–59). Doses should be decreased

when cannabinoids are combined with other drugs that work through calcium channels (such as gabapentin) to avoid excessive sedation (7). Cannabinoids should be avoided in pregnancy, nursing animals, and animals under 8 weeks of age (60). Controlled clinical trials and research focus mostly on innovative and emerging pain treatments, particularly for chronic and neuropathic pain (28, 61), since cannabinoids can prevent and control central and peripheral sensitization (62). It has been shown that they increase comfort and physical activity in dogs with OA, proving to be an effective treatment for chronic pain (30, 60, 63, 64).

Spatial distribution of cannabinoid receptors

In the CNS, a high density of cannabinoid receptors has been found in the cerebellum, brain stem, and medulla oblongata (65, 66). However, CB₁ can be found primarily in the spinal cord, periaqueductal gray, basal ganglia, cerebellum, and cerebral cortex (21, 67). Subsequent studies in animals

using immunohistochemistry have demonstrated the presence of CB1 receptors on the axon terminal in the presynaptic and postsynaptic membrane in astrocytes, oligodendrocytes, microglial cells, meninges (the dura mater), and the cerebral cortex (frontal lobe, neocortex, and gray matter), where this receptor is related to memory and association processes. Other sites where these receptors have been found to a lesser extent are the amygdala, nucleus accumbens, hypothalamus, thalamus, cerebellum, and midbrain (periaqueductal gray); these receptors participate in central antinociceptive and analgesic effects (12, 68). Receptors can also be found in the medulla oblongata, with a higher density in the spinal trigeminal nucleus and the olfactory bulb, where there is a higher expression, and their activation could be associated with the modulation of food intake. Receptors have also been identified in the parabrachial nucleus, areas of the brain stem, and the spinal cord (dorsal horn of lamina X and the ventral horn in the cervical, thoracic, and lumbar segments), some Purkinje cells, peripheral nerves, the outermost part of the skin, fibroblasts, and macrophages (39, 52, 69–71).

The retrograde inhibition of neurosecretion of acetylcholine, dopamine, GABA, histamine, 5HT, glutamine, cholecystokinin, D-aspartate, glycine, and noradrenaline has established that CB1 receptors are predominantly found in presynaptic fibers (56, 71, 72). Consequently, agonists of this type of receptor display more psychoactive adverse reactions in the CNS (hypothermia, ataxia, or euphoria), thus having a minor role in pain control despite various animal models studies show that they inhibit the production of cyclooxygenases (73). On the other hand, their use to treat seizures in dog and rodent models has increased. Cerebrospinal fluid samples were obtained from dogs suffering from idiopathic epilepsy, where an increased level of anandamide and endocannabinoid was observed compared to healthy dogs (74).

The expression of CB2 receptors is found in high densities in immune cells such as T and B lymphocytes, CD4, and CD8, which inhibits the release of interleukin th2, 10, 12, and interferon-gamma, natural killer cells, mast cells, macrophages, and neutrophils (14, 75). These receptors have been identified in the spleen, pancreas, thymus, lungs, tonsils, parotid and mandibular glands, Peyer's patches, basal ganglia, enteric neurons, striatum, synovial membrane, skin keratinocytes, as well as endothelial cells in blood vessels (4). As part of the CNS, they can be seen in the amygdala, hippocampus, cerebellum, cerebral cortex, nucleus accumbens, globus pallidus, and striatum (76, 77). In addition, these receptors are expressed in microglia and astroglia. Thus, this discovery has given rise to treatments for neuroinflammatory diseases based on therapeutic targets (51). There has been a debate surrounding the psychotropic ability of some cannabis extracts or synthetic derivatives due to the activation of CB1 receptors. However, it is unclear if CB2 receptors play a role in this process (3, 5, 26).

The expression of these receptors in dogs and cats made it possible to identify several receptors, such as GPR55, in the gastrointestinal tract, specifically the mucus (lamina propria and epithelial cells) and muscular layers, the stomach, pylorus, and colon. The PPAR α , PPAR γ , and TRPV1 receptors have been found in the lamina propria of the pylorus, duodenum, ileum, colon, enterochromaffin cells in the stomach, and endothelial cells in blood vessels. PPAR receptors have been associated with antinociceptive and anti-inflammatory effects and the prevention of hyperalgesia and allodynia. Alpha receptors have been used as therapeutic targets for treating allergy-related or eosinophilic skin diseases in dogs and cats (51, 52, 78, 79).

Therefore, the cannabinoid system regulates physiological and pathological processes in humans and animals and several tissues' nociceptive reflexes and inflammatory processes. As a result, the use of natural or synthetic cannabinoids inhibits the secretion of neurotransmitters and ions responsible for the modulation, projection, and perception of pain (72, 80), and this use in companion animals has become an object of study (67–70).

The role of cannabinoids in pain modulation

Acute, chronic, and neuropathic pain management uses new substances that assist traditional analgesics, such as NSAIDs, opioids, local anesthetics, and a ketamine. Therefore, cannabinoids are suggested as a complementary and effective alternative (7). To manage pain, drugs that intervene in the nociceptive pathway should be used as part of a multimodal protocol (20, 81), which is seen as a therapeutic advantage for the endocannabinoid system, as it is expressed in the ascending (perception) and descending (modulation) pathways of the periphery and terminal central of primary afferents (47). It can modulate stimuli in Rexed laminae I, II, and X of the dorsal horn in the spinal cord, where high concentrations of CB1 receptors can be found (71).

Several authors have reported that histological analysis, immunohistochemistry, and immunofluorescence revealed immunoreactivity in the cerebral cortex, cornu ammonis, and dentate gyrus of the hippocampus, where cells that react to CB1 were found, proving the presence and participation of cannabinoids in chronic pain control and patients with epilepsy (7, 58). These findings confirm that synthetic agonists found in cannabinoids or endocannabinoids prevent central sensitization due to the inhibition of GABA, glutamate, and voltage-dependent channels (72, 73, 82).

The selective activation of CB2 receptors has shown antinociception, anti-inflammatory, and neuroprotective effects in animal models such as rodents, dogs, and monkeys with OA, inflammation, spinal cord injury, and neuropathies (7, 28). As they activate antiallodynic effects, they inhibit the

hyperactivity of primary afferent fibers and decrease the release of neurotransmitters that act on nociceptors (28, 72, 83). This expression on the dorsal horn of the spinal cord creates a positive regulation in the presence of neuropathic and inflammatory pain (84, 85). As a result, this would confirm that in inflammatory lesions that affect nervous tissue, there is modulation by CB2 receptors.

The CB2 receptor is involved in immune processes by inhibiting the release of cytokines, thus, controlling oncological pain and preventing the progression of neuropathies, OA, arteriosclerosis, and neurodegenerative and neuroinflammatory diseases (86). Also, degenerative myelopathies, meningitis-arthritis, spinal spirocercosis, and epilepsy. An example can be found in patients with spinal cord injuries with higher activity and the presence of CB2 receptors on microglia (87).

The mechanisms that enable the CB2 receptors to produce analgesia involve several signaling pathways with cyclic AMP (AMPC), nerve growth factor (NGF), mitogen-activated kinase (MAP kinase), nuclear factor kappa B (NK-KB), calcium *via* JAK-STAT 1, ceramides, caspases, and c-Jun N-terminal kinases, which can be activated by second messengers such as Gi/o proteins (14, 36). A mechanism is still under research consisting of using synthetic agonists in mice, such as AM1241, which stimulated the release of β -endorphins that can activate μ -opioid receptors (46).

The involvement of CB1 and CB2 agonists in inflammation and pain reveals a promising therapeutic target. However, despite the evidence of its use and effectiveness in animals and humans, its effects are still under research. The role of CB1 and CB2 receptors is still an object of study since it can be associated with several intracellular mechanisms that modulate nociception (51, 88).

CBD has at least 76 different molecular targets of action. For example, it exerts its pain-relieving effects by interactions and modulation of inflammatory and nociceptive systems (as TRPV1 reverse agonist or COX2 inhibition). CBD has high activity in other ionotropic transient receptors potential channels, such as TRPA1, TRPV4, TRPV2, and TRPM8. Other groups of receptors that CBD binds are Gi-coupled receptors (GPR55, GPR18), PPARs, as opioid, 5-HT, or dopamine receptors (89, 90).

Efficacy of CBD in controlling pain

CBD has been studied to control pain in companion animals in chronic pain models, mainly related to OA (12, 30, 46, 63). Table 2 summarizes some clinical studies regarding this use (30, 63, 64, 91–93). Valastro et al. (62) identified and quantified endocannabinoids in synovial fluids of dogs with OA. They concluded that osteoarthritic knees had higher 2-AG concentrations, as oleoylethanolamide (OEA) presence, when compared with contralateral joints. This study tested the effect of modulating pain and inflammation by describing the presence

of endocannabinoid receptors in synovial fluids and adjacent inflamed tissues. This aspect is why cannabinoids effectively treat osteoarthritic pain in dogs, as mentioned by Brioschi et al. (63) and Kogan et al. (91), although in the first case, it was in multimodal therapy. However, the efficacy of CBD is still under discussion, as Mejia et al. (94) mentioned when measuring the safety and effect of CBD in controlling signs associated with pain caused by canine OA for 6 weeks. The authors concluded that there was no significant difference in the assessment of animals' gait and activity level of animals, describing that CBD as monotherapy does not have an appropriate analgesic efficacy to control pain. In contrast, some authors suggest that CBD or THC analgesic properties are dose-dependent (95, 96).

Adverse effects of cannabinoids

Cannabis intoxication is considered a clinical condition with a good prognosis in dogs as long as there are no comorbidities, complications, or co-ingestion of other potentially intoxicating substances. It is mentioned that the LD50 (median lethal dose) of oral THC in dogs appears to be >3 g/kg. Regarding CBD, there are no published data on its LD50, so it can be inferred that until now, in controlled clinical studies, this phenomenon has not been observed (12). However, regarding clinical safety and adverse effects in multidose administration schemes, it has been reported that high doses of 10 mg CBD + 0.5 mg THC/kg and medium doses of 5 mg CBD + 0.25 mg THC/kg; CBD metabolites were detected up to 48 h later. It also shows slow elimination phases accompanied by signs such as hyperesthesia (auditory/visual/tactile stimuli) and proprioceptive deficits in the first 2 h of administration, which disappeared within 4–6 h after the presentation (37). Other adverse events observed in the high-dose group included ptialism (1/6 dogs), urinary incontinence (1/6 dogs), and vomiting (3/6 dogs). On the other hand, animals treated with single and multi-dose neurological changes (mydriasis, ataxia, hyperacusis, and delayed reflex responses) were detected 2 h after administering the single dose of 5 mg CBD/kg. However, the signs significantly decreased or were absent within the first 6 h (37).

On the other hand, Brioschi et al. (63) report the presence of minimal ptialism in 22% of the animals treated with CBD (2 of 9 dogs), in addition to somnolence and mild ataxia in 1 of 9 experimental subjects. Similarly, Vaughn et al. (97) found mild adverse effects in 94.9% of the cases, moderate effects in 4.4% of the animals under study, and only 0.8% had severe effects, such as lethargy, hypothermia, and ataxia. It is worth mentioning that these effects were attributed to a THC preparation, which implies that these products' chemical and pharmacokinetic characteristics could be the main responsible for the appearance of adverse neurological signs. Likewise, in a similar study in dogs medicated with a repeated dose of 12 mg/kg of a cannabis extract orally for 28 days, mild gastrointestinal

TABLE 2 Clinical studies of the use of CBD in chronic pain models in dogs and cats.

Pain model	Compound	Species	Route	Dosage	Period	Results	Reference
OA	CBD oil	Dog	Oral	2 mg/kg/12 h	4 w	Based on the Hudson Activity Scores, the activity level increased. Pain was significantly decreased, as was shown by the Canine Brief Pain Inventory scoring system ($p < 0.01$). Concomitant use of NSAIDs reduced lameness scores ($p = 0.03$). Veterinary pain scores showed a decrease from baseline in dogs on NSAIDs ($p < 0.01$)	Gamble et al. (30)
OA	CBD oil	Dog	Oromucosal	2 mg/kg/12 h	12 w	According to the Canine Brief Pain Inventory scoring system, the addition of CBD to anti-inflammatory drugs (firocoxib or prednisone), gabapentin and amitriptyline (multimodal therapy) reduced the pain severity ($p = 0.0002$ to 0.016) and increased the Quality-of-Life index ($p = 0.003$)	Brioschi et al. (63)
Lameness (OA)	Naked CBD Liposomal CBD	Dog	Oral	0.5 mg/kg or 1.2 mg/kg for naked CBD or 20 mg/day liposomal CBD (three groups)	4 w	Significantly decreased pain ($p \leq 0.01$) and increased mobility (walking, running, and standing position) in a dose-dependent association (50 mg/kg naked CBD or 20 mg/kg liposomal CBD), and the effect remained 15 days after cessation of therapy	Verrico et al. (64)
Chronic maladaptive (OA)	CBD oil	Dog	Oral	0.25 mg/kg/12 h 0.5–0.75 mg/kg/12 h	90 d	Using the Cincinnati Orthopedic Disability index as a pain assessment every 2 weeks, CBD reduced the pain scores from 3.2 ± 2.2 to 0.97 ± 0.81 Additionally, gabapentin doses were reduced by 20 to 40% in some dogs	Kogan et al. (91)
OA	CBD	Dog	Oral	1 mg/kg/12 h	30 d	From day 3, the pain was reduced by 32% (81 to 54 points by day 30), according to the Canine Brief Pain Inventory in dogs	Furtado de Álava (92)
Sarcoma	THC/CBD oil	Cat	Topical oral	0.2 mg/kg/12 h 0.05 cc	10 d	Extracted cannabis oil diluted with normal saline (1:5) reduced the pain caused by the sarcoma growth and reduced its size from 5 to 1.5 cm	Buranakarn (93)

d, days; h, hours; w, weeks; OA, osteoarthritis.

signs such as hypersalivation were generated, in addition to an increase in serum alkaline phosphatase (98). This reveals that these adverse effects are related to the exposure time, type of product, and dose used.

Janeczek et al. (99) reported the adverse effects of phytocannabinoid intoxication in a cat, describing consciousness disorders, seizures, ataxia, depression, anxiety, vocalization, hypersalivation, diarrhea, vomiting, bradycardia or tachycardia, hypothermia, and mydriasis (99). From a comparative point of view, these effects are similar to those reported in dogs. However, according to Kulpa et al. (33), the safety and tolerability of oral staggered doses of cannabis oil produce mild and transient adverse effects, even though the administration of CBD oil was carried out at a dose of 30.5 mg/kg were lethargy, hypothermia, ataxia, and nictitating membrane protrusion were observed, which did not require medical intervention for resolution. Unfortunately, the lack of related information on this species is limited, making it difficult to compare the incidence of adverse effects reported in dogs and corroborate its safety in cats. In such a way, it is necessary to emphasize that despite the clinical usefulness of cannabinoids, the present adverse effects cannot be ignored, which must be controlled and resolved by the veterinarian during their use.

Study perspectives, limitations of its clinical application, and therapeutic evaluations of the use of cannabinoids in rodents models, dogs, and cats

Studies focusing on cannabinoids used in veterinary medicine predominate in laboratory animals rather than domestic species, particularly dogs and cats. These studies have enabled the development of synthetic agonists of cannabinoid receptors based on their chemical structure and further research regarding the specific distribution of cannabinoid receptors in the CNS. Due to the limitations of these drugs, they are currently being used only *in vitro* and in test animals such as mice, rats, or guinea pigs to transfer them to human medicine (88). However, WIN55,212-2, a synthetic agonist, has been used as an anticonvulsant, and it is aimed at dogs suffering from idiopathic epilepsy that have shown increased levels of anandamide and endocannabinoids in their cerebrospinal fluid, compared to healthy animals (67).

Gamble et al. (30) recently tested CBD oil's safety and analgesic efficiency at a concentration of 10 mg/mL of CBD (as an equal mix of CBD and CBDA) and 0.24 mg/mL; 0.27 mg/mL of THC and cannabichromene respectively, in dogs with chronic pain caused by OA. Each dog received a 2 mg/kg and an 8 mg/kg oral dosage for 4 weeks and showed an elimination half-life of 4.2 h without side effects. The evaluations to assess the analgesic efficiency and Hudson activity scores showed a significant

decrease in pain degree with the dosage used. During the trial, dogs were only allowed to receive NSAIDs, fish oil, and/or glucosamine/chondroitin sulfate without changing in these medications for 4 weeks before or during the 10-week study period as a standard of care for the disease process. Regarding clinical safety and toxicity tests, no significant difference was noted in BUN, creatinine, or phosphorus between dogs treated with CBD oil vs. the placebo oil, while NSAID treatment resulted in a higher creatinine concentration. In this study, an increase in ALP activity was also reported in nine dogs treated with CBD, explaining that this effect may be due to the induction of oxidative metabolism in the liver mediated by cytochrome p450.

The clinical efficiency of cannabinoids to treat oncological pain in veterinary patients has also been proved after it was shown that nociceptive reactions result from the stimulation of visceral and somatic afferent pathways that could cause neuropathic pain (3, 7). Inflammatory reactions are common in cancer and can be treated with opioids and NSAIDs (100). This condition favors the presence of fatigue, decreased mobility, cognitive disorders, urinary conditions, and paraneoplastic syndrome-related pain (moderate to severe). As a result, using natural derivatives such as cannabinoids offers a safe alternative for pain control. In addition, this neoplastic activity would be beneficial to control adverse reactions caused by antineoplastics or cancer itself (101).

Johnson et al. (102) conducted a follow-up study on 43 human patients with advanced cancer-related pain. A THC/CBD spray was used to assess efficacy and tolerability to opioids for 3 weeks. There was a significant reduction in pain, as seen in the scores from questionnaires that represented pain. No safety issues associated with the use of this spray were reported. In veterinary medicine, CBD has shown promising results as a single prescription or in combination with mitoxantrone and vinblastine for the treatment of canine urothelial carcinoma cells (103), in canine cutaneous mast cell tumor (104) and even as multimodal compassionate pain therapy reported in a case of a dog with OA and testicular neoplasia that was medicated with robencoxib, gabapentin, and a formulation of liposomal CBD injected subcutaneously (105).

Pharmacological interactions like the ones mentioned above have already been studied, and the use of cannabinoids created a synergic effect with opioid agonists (106). Similar studies revealed an analgesic efficacy in rats that were given a combination of subcutaneous morphine along with intraperitoneal administration of THC at high (100 and 4 mg/kg, respectively) and low dosages (75 mg/kg and 4 mg/kg), both of which produced analgesia. In addition, this combination prevented tolerability to opioids; these results are similar to other studies that have used CB receptor agonists (57–59). An explanation for this synergic effect is that both drugs produce analgesia through signaling pathways linked to second messengers such as protein G (14, 107).

Regarding the development of pharmaceuticals, the University of Cambridge manufactured a product called Sativex[®] equivalent to 8.1 mg of Δ^9 -THC:7.5 mg of CBD), which has been used in human medicine and is currently used for controlled clinical tests in animals such as dogs and cats (3, 87).

Additionally, it has been reported that CBD can reduce the consumption of inhalational anesthetics in animal models. In this regard, the administration of CBD and pure opioids such as morphine significantly reduces the consumption of inhalational anesthetics (108). Other studies indicate that a single dose of cannabinoids can modify the anesthetic depth with inhalational agents, where electroencephalographic alterations can be monitored through the bispectral index (BIS) (109). However, a clear discussion is necessary if this benefit could exceed the pain control provided by this substance (110). Regarding other interactions, a potentiation effect with benzodiazepines has been described due to the GABA's binding affinity and degradation. With gabapentin, CBD enhances its analgesic effect, and the doses can be reduced. On the other hand, the action of cannabinoids on 5HT-1A, 5HT-2A, and 5HT-3A receptors can increase the effects of serotonin syndrome (7). Concerning other anesthetics, studies in rats have shown that ketamine can function as an exogenous agonist of CBD, releasing anandamide (110), and propofol inhibits CB1 and CB2-mediated sympathetic responses, so its effect can be prolonged (111), as with barbiturates and alfaxalone (7).

Conclusions

The study of the endocannabinoid system, its ligands, receptors, mechanism of action, and signaling, has led to research showing that cannabis extracts and synthetic derivatives are an effective therapeutic alternative for the multimodal management of pain. The evidence suggests that cannabinoids can be used in veterinary medicine to treat acute, chronic and neuropathic pain due to their ability to prevent peripheral and central sensitization (112).

References

- Marcoux RM, Larrat EP, Vogenberg FR. Medical marijuana and related legal aspects. *P T*. (2013) 38:612–9.
- Stogdale L. January Veterinary Medical Ethics — Cannabinoids to treat dogs and cats. *Can Vet J*. (2019) 60:345.
- Landa L, Sulcova A, Gbelec P. The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. *Vet Med*. (2016) 61:111–22. doi: 10.17221/8762-VETMED
- Hollinshead SP, Tidwell MW, Palmer J, Guidetti R, Sanderson A, Johnson MP, et al. Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain. *J Med Chem*. (2013) 56:5722–33. doi: 10.1021/jm400305d
- Kogan L, Hellyer B, Silcox S, Schoenfeld-Tacher R. Canadian dog owners' use and perceptions of cannabis products. *Can Vet J*. (2019) 60: 749–55.

However, since the endocannabinoid system is a signaling pathway that regulates several actions, its interaction with different endogenous ligands and neurotransmitter modulation can have beneficial effects on patients suffering from seizures, contact and atopic dermatitis, epilepsy, degenerative myelopathies, asthma, diabetes, glaucoma, retinitis pigmentosa, and inflammatory diseases. These compounds also possess antineoplastic, appetite-stimulating, and antiemetic properties (3, 90, 113–116).

According to some clinical trials, CBD is a potential analgesic drug for chronic pain control in companion animals, although it seems to have a dose-dependent fashion. These results show the importance of studying cannabinoids and their effect on the CNS and PNS and the expression and role of its receptors in companion animals as a potential field of study for veterinary medicine to offer health benefits and wellbeing to future patients.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

6. ElSohly M. Chemical constituents of cannabis. In: Grotenhermen F, Russo F, editors. *Cannabis and Cannabinoids Pharmacology, Toxicology and Therapeutic Potential*. New York, USA: Haworth Press (2002). p. 27–36
7. Copas G, Amazonas E, Brandon S. The pharmacology of cannabinoids. In: Cital S, Kramer K, Hughston L, Gaynor J., editors. *Cannabis Therapy in Veterinary Medicine. A Complete Guide*. Cham, Switzerland: Springer (2021). p. 17–59 doi: 10.1007/978-3-030-68317-7_2
8. Mechoulam R, Hanuš L, A. historical overview of chemical research on cannabinoids. *Chem Phys Lipids*. (2000) 108:1–13. doi: 10.1016/S0009-3084(00)00184-5
9. Mechoulam R, Ben Shabat S, Hanuš L, Fride E, Vogel Z, Bayewitch M, et al. Endogenous cannabinoid ligands — chemical and biological studies. *J Lipid Mediat Cell Signal*. (1996) 14:45–9. doi: 10.1016/0929-7855(96)01507-6
10. Fisar Z. Phytocannabinoids and Endocannabinoids. *Curr Drug Abuse Rev*. (2009) 2:51–75. doi: 10.2174/1874473710902010051
11. Mechoulam R, Devane W, Glaser R. Cannabinoid geometry and biological activity. In: Murphy L, Bartke A, editors. *Marijuana/Cannabinoids: Neurobiology and Neurophysiology*. Florida, USA: CRC Press. (1992). p. 1–33 doi: 10.1201/9780429276279-1
12. Coelho RC, de Leme FA, Moreira FE, Branco MT, Melo SM, de Melo E. Current review of hemp-based medicines in dogs. *J Vet Pharmacol Ther*. (2021) 44:870–882. doi: 10.1111/jvp.13016
13. Earleywine M. *Understanding Marijuana: A New Look at the Scientific Evidence*. New York, USA: University Press (2002). 1–344 p.
14. Howlett AC. The cannabinoid receptors. *Prostaglandins Other Lipid Mediat*. (2002) 68:619–631. doi: 10.1016/S0090-6980(02)00060-6
15. Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. *Iran J Psychiatry*. (2012) 7:149–56.
16. Pertwee RG. Pharmacological actions of cannabinoids. *Handb Exp Pharmacol*. (2005) 168:1–51. doi: 10.1007/3-540-26573-2_1
17. McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. *Br J Pharmacol*. (2007) 152:583–93. doi: 10.1038/sj.bjp.0707399
18. Grotenhermen F. Pharmacology of cannabinoids. *Neuro Endocrinol Lett*. (2005) 25:14–23.
19. Morales P, Reggio PH, Jagerovic N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. *Front Pharmacol*. (2017) 8:422. doi: 10.3389/fphar.2017.00422
20. Guindon J, Hohmann AAA. The endocannabinoid system and pain. *CNS Neurol Disord - Drug Targets*. (2009) 8:403–21. doi: 10.2174/187152709789824660
21. Kenakin T. New concepts in pharmacological efficacy at 7TM receptors: IUPHAR Review 2. *Br J Pharmacol*. (2013) 168:554–75. doi: 10.1111/j.1476-5381.2012.02223.x
22. Grotenhermen F. Cannabinoids and the endocannabinoids system. *Cannabinoids*. (2006) 1:10–4.
23. Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. *Animals*. (2019) 9:832. doi: 10.3390/ani9100832
24. Yu CHJ, Rupasinghe HPV. Cannabidiol-based natural health products for companion animals: recent advances in the management of anxiety, pain, and inflammation. *Res Vet Sci*. (2021) 140:38–46. doi: 10.1016/j.rvsc.2021.08.001
25. Silver R, Silcox S, Loughton D. Product selection and dosing considerations. In: Cital S, Kramer K, Hughston L, Gaynor J, editors. *Cannabis therapy in veterinary medicine. A complete guide*. Switzerland: Springer (2021). p. 307–342 doi: 10.1007/978-3-030-68317-7_13
26. Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. *Dtsch Aerzteblatt Online*. (2012) 3:495. doi: 10.3238/arztebl.2012.0495
27. Presley B, Jansen-Varnum S, Logan B. Analysis of synthetic cannabinoids in botanical material: a review of analytical methods and findings. *Forensic Sci Revision*. (2013) 25:27–46.
28. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. *J Anal Toxicol*. (1992) 16:276–82. doi: 10.1093/jat/16.5.276
29. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet*. (2003) 42:327–60. doi: 10.2165/00003088-200342040-00003
30. Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, et al. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. *Front Vet Sci*. (2018) 5:165. doi: 10.3389/fvets.2018.00165
31. Wakshlag JJ, Schwark WS, Deabold KA, Talsma BN, Cital S, Lyubimov A, et al. Pharmacokinetics of cannabidiol, cannabidiolic acid, 89-tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract. *Front Vet Sci*. (2020) 7:505. doi: 10.3389/fvets.2020.00505
32. Hannon MB, Deabold KA, Talsma BN, Lyubimov A, Iqbal A, Zakharov A, et al. Serum cannabidiol, tetrahydrocannabinol. (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. *J Vet Pharmacol Ther*. (2020) 43:508–11. doi: 10.1111/jvp.12896
33. Kulpa JE, Paulionis LJ, Eglit GM, Vaughn DM. Safety and tolerability of escalating cannabinoid doses in healthy cats. *J Feline Med Surg*. (2021) 23:1162–75. doi: 10.1177/1098612X211004215
34. Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. *Drug Metab Dispos*. (1988) 16:469–72.
35. Bartner L, McGrath S, Sangeeta R, Hyatt L, Wittenburg L. Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. *Can J Vet Res*. (2018) 82:178–83.
36. Fernández-Trapero M, Pérez-Díaz C, Espejo-Porras F, de Lago E, Fernández-Ruiz J. Pharmacokinetics of sativex® in dogs: towards a potential cannabinoid-based therapy for canine disorders. *Biomolecules*. (2020) 10:279. doi: 10.3390/biom10020279
37. Chicoine A, Illing K, Vuong S, Pinto KR, Alcorn J, Cosford K. Pharmacokinetic and Safety evaluation of various oral doses of a novel 1:20 THC:CBD cannabis herbal extract in dogs. *Front Vet Sci*. (2020) 7:34041. doi: 10.3389/fvets.2020.583404
38. Silver RJ. The endocannabinoid system of animals. *Animals*. (2019) 9:686. doi: 10.3390/ani9090686
39. Rodríguez de Fonseca F, Del Aarco I, Bermudez-Silva FJ, Bilbao A, Cipitelli A, Navarro M, et al. The endocannabinoid system: Physiology and pharmacology. *Alcohol Alcohol*. (2005) 40:2–14. doi: 10.1093/alcalc/agh110
40. Starowicz K, Finn DP. Cannabinoids and pain: sites and mechanisms of action. *Adv Pharmacol*. (2017) 45:437–75. doi: 10.1016/bs.apha.2017.05.003
41. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. *Int J Mol Sci*. (2018) 19:833. doi: 10.3390/ijms19030833
42. Davis MP. Cannabinoids in pain management: CB1, CB2, and non-classic receptor ligands. *Expert Opin Investig Drugs*. (2014) 23:1123–40. doi: 10.1517/13543784.2014.918603
43. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. *Annu Rev Physiol*. (2009) 71:283–306. doi: 10.1146/annurev.physiol.010908.163149
44. Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, et al. Cannabinoid CB 2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. *Proc Natl Acad Sci*. (2014) 111:5007–2015. doi: 10.1073/pnas.1413210111
45. Vasileiou I, Fotopoulou G, Matzourani M, Patsouris E, Theocharis S. Evidence for the involvement of cannabinoid receptors' polymorphisms in the pathophysiology of human diseases. *Expert Opin Ther Targets*. (2013) 17:363–77. doi: 10.1517/14728222.2013.754426
46. Beltramo M. Cannabinoid Type 2 Receptor as a target for chronic - pain. *Mini-Reviews Med Chem*. (2009) 9:11–25. doi: 10.2174/138955709787001785
47. Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2. (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review. *Pharmacol Biochem Behav*. (2008) 90:501–11. doi: 10.1016/j.pbb.2008.05.010
48. Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. *Brain Res*. (1999) 822:17–25. doi: 10.1016/S0006-8993(98)01321-3
49. Ameri A. The effects of cannabinoids on the brain. *Prog Neurobiol*. (1999) 58:315–48. doi: 10.1016/S0301-0082(98)00087-2
50. Marichal-Cancino B, Fajardo-Valdez A, Ruiz-Contreras A, Mendez-Díaz M, Prospero-García O. Advances in the physiology of GPR55 in the central nervous system. *Curr Neuropharmacol*. (2017) 15:5441. doi: 10.2174/1570159X14666160729155441
51. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. *Eur J Neurosci*. (2003) 17:2750–4. doi: 10.1046/j.1460-9568.2003.02704.x

52. Galiazzo G, Giancola F, Stanzani A, Fracassi F, Bernardini C, Forni M, et al. Localization of cannabinoid receptors CB1, CB2, GPR55, and PPAR α in the canine gastrointestinal tract. *Histochem Cell Biol.* (2018) 150:187–205. doi: 10.1007/s00418-018-1684-7
53. Stanzani A, Galiazzo G, Giancola F, Tagliavia C, De Silva M, Pietra M, et al. Localization of cannabinoid and cannabinoid related receptors in the cat gastrointestinal tract. *Histochem Cell Biol.* (2020) 153:339–56. doi: 10.1007/s00418-020-01854-0
54. Cabral G, Griffin-Thomas L. Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. *Endocrine Metab Immune Disord Targets.* (2008) 8:159–72. doi: 10.2174/187153008785700118
55. Walter L, Stella N. Cannabinoids and neuroinflammation. *Br J Pharmacol.* (2004) 141:775–85. doi: 10.1038/sj.bjp.0705667
56. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms? a review of recent preclinical data. *Psychopharmacology.* (2003) 169:115–34. doi: 10.1007/s00213-003-1485-z
57. Cichewicz DL, McCarthy EA. Antinociceptive synergy between δ 9 - tetrahydrocannabinol and opioids after oral administration. *J Pharmacol Exp Ther.* (2003) 304:1010–5. doi: 10.1124/jpet.102.045575
58. Bailey CP, Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. *Curr Opin Pharmacol.* (2005) 5:60–8. doi: 10.1016/j.coph.2004.08.012
59. Grotenhermen F. Cannabinoids. *Curr Drug Target -CNS Neurol Disord.* (2005) 4:507–30. doi: 10.2174/156800705774322111
60. Monteiro BP, Lascelles BDX, Murrell J, Robertson S, Steagall PVM, Wright B. 2022 WSAVA guidelines for the recognition, assessment and treatment of pain. *J Small Anim Pract.* (2022). 35:450.
61. Cox ML, Haller VL, Welch SP. Synergy between Δ 9-tetrahydrocannabinol and morphine in the arthritic rat. *Eur J Pharmacol.* (2007) 567:125–30. doi: 10.1016/j.ejphar.2007.04.010
62. Valastro C, Campanile D, Marinaro M, Franchini D, Piscitelli F, Verde R, et al. Characterization of endocannabinoids and related acylethanolamides in the synovial fluid of dogs with osteoarthritis: a pilot study. *BMC Vet Res.* (2017) 13:309. doi: 10.1186/s12917-017-1245-7
63. Brioschi FA, Di Cesare F, Gioeni D, Rabbogliatti V, Ferrari F, D'Urso ES, et al. Oral transcutaneous cannabidiol oil formulation as part of a multimodal analgesic regimen: effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. *Animals.* (2020) 10:1505. doi: 10.3390/ani10091505
64. Verrico CD, Wesson S, Konduri V, Hofferek CJ, Vazquez-Perez J, Blair E, et al. randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. *Pain.* (2020) 161:2191–202. doi: 10.1097/j.pain.0000000000001896
65. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. *Life Sci.* (2004) 74:1317–24. doi: 10.1016/j.lfs.2003.09.038
66. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. *Proc Natl Acad Sci.* (1990) 87:1932–6. doi: 10.1073/pnas.87.5.1932
67. Cristino L, Imperatore R, Di Marzo V. Techniques for the cellular and subcellular localization of endocannabinoid receptors and enzymes in the mammalian brain. *Methods Enzymologic.* (2017) 63:61–98. doi: 10.1016/bs.mie.2017.05.003
68. Freundt-Revilla J, Kegler K, Baumgärtner W, Tipold A. Spatial distribution of cannabinoid receptor type 1. (CB1) in normal canine central and peripheral nervous system. *PLoS ONE.* (2017) 12:e0181064. doi: 10.1371/journal.pone.0181064
69. Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. *Life Sci.* (1995) 56:2103–9. doi: 10.1016/0024-3205(95)00195-C
70. Glass M, Faull RL, Dragunow M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience.* (1997) 77:299–318. doi: 10.1016/S0306-4522(96)00428-9
71. Tsou K, Brown S, Sañudo-Peña M, Mackie K, Walker J. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. *Neuroscience.* (1998) 83:393–411. doi: 10.1016/S0306-4522(97)00436-3
72. Rea K, Roche M, Finn DP. Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. *Br J Pharmacol.* (2007) 152:633–48. doi: 10.1038/sj.bjp.0707440
73. Farquhar-Smith WP, Egertová M, Bradbury EJ, McMahon SB, Rice ASC, Elphick MR. Cannabinoid CB1 receptor expression in rat spinal cord. *Mol Cell Neurosci.* (2000) 15:510–21. doi: 10.1006/mcne.2000.0844
74. Gesell FK, Zoerner AA, Brauer C, Engeli S, Tsikas D, Tipold A. Alterations of endocannabinoids in cerebrospinal fluid of dogs with epileptic seizure disorder. *BMC Vet Res.* (2013) 9:262. doi: 10.1186/1746-6148-9-262
75. Echeverria-Villalobos M, Todeschini AB, Stoicea N, Fiorda-Diaz J, Weaver T, Bergese SD. Perioperative care of cannabis users: a comprehensive review of pharmacological and anesthetic considerations. *J Clin Anesth.* (2019) 57:41–9. doi: 10.1016/j.jclinane.2019.03.011
76. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. *Pharmacol Ther.* (1997) 74:129–80. doi: 10.1016/S0163-7258(97)82001-3
77. Galiegue S, Mary S, Marchand J, Dussosoy D, Carriere D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem.* (1995) 232:54–61. doi: 10.1111/j.1432-1033.1995.tb20780.x
78. Li Y, Kim J. Distinct roles of neuronal and microglial CB2 cannabinoid receptors in the mouse hippocampus. *Neuroscience.* (2017) 363:11–25. doi: 10.1016/j.neuroscience.2017.08.053
79. Miragliotta V, Ricci PL, Albanese F, Pirone A, Tognotti D, Abramo F. Cannabinoid receptor types 1 and 2 and peroxisome proliferator-activated receptor- α : distribution in the skin of clinically healthy cats and cats with hypersensitivity dermatitis. *Vet Dermatol.* (2018) 29:316–e111. doi: 10.1111/vde.12658
80. Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza A V, et al. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB 2 receptor agonist exhibiting analgesic activity in rodent pain models. *Br J Pharmacol.* (2008) 153:390–401. doi: 10.1038/sj.bjp.0707568
81. Suzuki R, Dickenson A. Spinal and supraspinal contributions to central sensitization in peripheral neuropathy. *Neurosignals.* (2005) 14:175–81. doi: 10.1159/000087656
82. Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. *Curr Opin Support Palliat Care.* (2014) 8:143–51. doi: 10.1097/SPC.0000000000000055
83. Trettel J, Levine ES. Endocannabinoids mediate rapid retrograde signaling at interneuron \rightarrow pyramidal neuron synapses of the neocortex. *J Neurophysiol.* (2003) 89:2334–8. doi: 10.1152/jn.01037.2002
84. LaBuda CJ, Koblisch M, Little PJ. Cannabinoid CB2 receptor agonist activity in the hindpaw incision. *Eur J Pharmacol.* (2005) 527:172–4. doi: 10.1016/j.ejphar.2005.10.020
85. Milligan ED, Twining C, Chacur M, Biedenkapp J, O'Connor K, Poole S, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. *J Neurosci.* (2003) 23:1026–40. doi: 10.1523/JNEUROSCI.23-03-01026.2003
86. Zogopoulos P, Vasileiou I, Patsouris E, Theocharis SE. The role of endocannabinoids in pain modulation. *Fundam Clin Pharmacol.* (2013) 27:64–80. doi: 10.1111/fcp.12008
87. Miller LK, Devi LA. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. *Pharmacol Rev.* (2011) 63:461–70. doi: 10.1124/pr.110.003491
88. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. *Proc Natl Acad Sci.* (2005) 102:3093–8. doi: 10.1073/pnas.0409888102
89. Vučković S, Srebro D, Vujović KS, Vučetić C, Prostran M. Cannabinoids and pain: new insights from old molecules. *Front Pharmacol.* (2018) 9:1259. doi: 10.3389/fphar.2018.01259
90. Mlost J, Bryk M, Starowicz K. Cannabidiol for pain treatment: [0mm][4mm]focus on pharmacology and mechanism of action. *Int J Mol Sci.* (2020) 21:8870. doi: 10.3390/ijms21228870
91. Kogan L, Hellyer P, Downing R. The use of cannabidiol-rich hemp oil extract to treat canine osteoarthritis-related pain: a pilot study. *J Am Anim Hospital Assoc.* (2020) 58:1–10.
92. Furtado de Álava A. *Cannabis de Uso Medicinal para el Tratamiento de Dolor Crónico de un Labrador Retriever con Osteoartritis.* Relato de Caso Universidad de la República, Facultad de Veterinaria, Montevideo (2019).
93. Buranakarn V. Sarcoma cancer treatment using extracted cannabis oil in cat. *Int J Sci Innov Technol.* (2020) 3:35–40.
94. Mejia S, Duerr FM, Griffenhagen G, McGrath S. Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs. *J Am Anim Hosp Assoc.* (2021) 57:81–90. doi: 10.5326/JAHA-MS-7119
95. Genaro K, Fabris D, Arantes ALF, Zuairi AW, Crippa JAS, Prado WA. Cannabidiol is a potential therapeutic for the affective-motivational dimension of incision pain in rats. *Front Pharmacol.* (2017) 8:391. doi: 10.3389/fphar.2017.00391

96. Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. *Eur J Pain*. (2016) 20:936–48. doi: 10.1002/ejp.818
97. Vaughn D, Kulpa J, Paulionis L. Preliminary investigation of the safety of escalating cannabinoid doses in healthy dogs. *Front Vet Sci*. (2020) 7:51. doi: 10.3389/fvets.2020.00051
98. Vaughn DM, Paulionis LJ, Kulpa JE. Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs. *Am J Vet Res*. (2021) 82:405–16. doi: 10.2460/ajvr.82.5.405
99. Janeczek A, Zawadzki M, Szpot P, Niedzwiedz A. Marijuana intoxication in a cat. *Acta Vet Scand*. (2018) 60:44. doi: 10.1186/s13028-018-0398-0
100. Looney A. Oncology pain in veterinary patients. *Top Companion Anim Med*. (2010) 25:32–44. doi: 10.1053/j.tcam.2009.10.008
101. Queiroga FL, Perez-Alenza MD, Silvan G, Peña L, Lopes C, Illera JC. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. *Anticancer Res*. 25:4269–75.
102. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD Oromucosal Spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. *J Pain Symptom Manage*. (2013) 46:207–18. doi: 10.1016/j.jpainsymman.2012.07.014
103. Inkol JM, Hocker SE, Mutsaers AJ. Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells. *PLoS ONE*. (2021) 16:e0255591. doi: 10.1371/journal.pone.0255591
104. Rinaldi V, Boari A, Ressel L, Bongiovanni L, Crisi PE, Cabibbo E, et al. Expression of cannabinoid receptors CB1 and CB2 in canine cutaneous mast cell tumours. *Res Vet Sci*. (2022) 152:530–6. doi: 10.1016/j.rvsc.2022.09.013
105. Shilo-Benjamini Y, Cern A, Zilbersheid D, Hod A, Lavy E, Barasch D, Barenholz Y. A case report of subcutaneously injected liposomal cannabidiol formulation used as a compassion therapy for pain management in a dog. *Front Vet Sci*. (2022) 9: doi: 10.3389/fvets.2022.892306
106. Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. *Pharmacol Biochem Behav*. (2001) 69:239–49. doi: 10.1016/S0091-3057(01)00531-7
107. Elikottil J, Gupta P, Gupta K, Elikottil J, Elikottil J, Gupta P, et al. The analgesic potential of cannabinoids. *J Opioid Manag*. (2009) 5:341–57. doi: 10.5055/jom.2009.0034
108. Orden C, Santos M, Ceprian M, Tendillo FJ. The effect of cannabidiol on sevoflurane minimum alveolar concentration reduction produced by morphine in rats. *Vet Anaesth Analg*. (2021) 48:74–81. doi: 10.1016/j.vaa.2020.04.017
109. Ibera C, Shalom B, Saifi F, Shrufer J, Davidson E. Effects of cannabis extract premedication on anesthetic depth. *Harefuah*. (2018) 157:162–6.
110. Ferreira RCM, Castor MGM, Piscitelli F, Di Marzo V, Duarte IDG, Romero TRL. The involvement of the endocannabinoid system in the peripheral antinociceptive action of ketamine. *J Pain*. (2018) 19:487–95. doi: 10.1016/j.jpain.2017.12.002
111. Kumar SSH, Dass LL, Sharma AK. Cannabis Indica. (Bhang) extract as preanaesthetic to propofol anaesthesia in dogs. *J Appl Anim Res*. (2010) 37:125–7. doi: 10.1080/09712119.2010.9707109
112. Mosley C, Gaynor J, Cital S, Brassard J. Cannabinoids for pain management. *Cannabis Therapy in Veterinary Medicine. A complete Guide*. Cham, Switzerland: Springer (2021). p. 117–142 doi: 10.1007/978-3-030-68317-7_5
113. Campora L, Miragliotta V, Ricci E, Cristino L, Di Marzo V, Albanese F, et al. Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. *Am J Vet Res*. (2012) 73:988–95. doi: 10.2460/ajvr.73.7.988
114. Morris EM, Kitts-Morgan SE, Spangler DM, Gebert J, Vanzant ES, McLeod KR, et al. Feeding cannabidiol. (CBD)-containing treats did not affect canine daily voluntary activity. *Front Vet Sci*. (2021) 8:5667. doi: 10.3389/fvets.2021.645667
115. Karler R, Turkkanis SA. The cannabinoids as potential antiepileptics. *J Clin Pharmacol*. (1981) 21:437S–48S. doi: 10.1002/j.1552-4604.1981.tb02624.x
116. McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. *J Am Vet Med Assoc*. (2019) 254:1301–8. doi: 10.2460/javma.254.11